<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article xml:lang="en" dtd-version="1.3" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">HF</journal-id>
      <journal-id journal-id-type="doi">10.56578</journal-id>
      <journal-title-group>
        <journal-title>Healthcraft Frontiers</journal-title>
        <abbrev-journal-title abbrev-type="issn">Healthcraft. Front.</abbrev-journal-title>
        <abbrev-journal-title abbrev-type="publisher">HF</abbrev-journal-title>
      </journal-title-group>
      <issn publication-format="electronic">3005-799X</issn>
      <issn publication-format="print">3005-7981</issn>
      <publisher>
        <publisher-name>Acadlore</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">AR-fxFjORe4Q5q0lT00Y-dlY62s9tKLI-D5</article-id>
      <article-id pub-id-type="doi">10.56578/hf020404</article-id>
      <article-categories>
        <subj-group>
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clinical Profile and Management of Diabetic Foot Infection at Hayatabad Medical Complex, Peshawar</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" rid="aff_1">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-0269-3766</contrib-id>
          <name>
            <surname>Ahmad</surname>
            <given-names>Naseer</given-names>
          </name>
          <email>nahmad@uswat.edu.pk</email>
        </contrib>
        <contrib contrib-type="author" rid="aff_2">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-7892-614X</contrib-id>
          <name>
            <surname>Mehmood</surname>
            <given-names>Bilal</given-names>
          </name>
          <email>sheraz.msep@iiu.pk</email>
        </contrib>
        <aff id="aff_1">Centre for Biotechnology and Microbiology, University of Swat, 19200 Mingora, Pakistan</aff>
        <aff id="aff_2">Hayatabad Medical Complex, 25000 Peshawar, Pakistan</aff>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>30</day>
        <month>12</month>
        <year>2024</year>
      </pub-date>
      <volume>2</volume>
      <issue>4</issue>
      <fpage>217</fpage>
      <lpage>224</lpage>
      <page-range>217-224</page-range>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>10</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>12</month>
          <year>2024</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>©2024 by the author(s)</copyright-statement>
        <copyright-year>2024</copyright-year>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p> Published by Acadlore Publishing Services Limited, Hong Kong. This article is available for free download and can be reused and cited, provided that the original published version is credited, under the CC BY 4.0 license.</license-p>
        </license>
      </permissions>
      <abstract><p>Diabetic foot infection (DFI) represents a severe and potentially limb-threatening complication of long-standing and poorly controlled diabetes mellitus, a condition currently affecting over 422 million individuals globally and associated with more than 2 million annual deaths. This retrospective observational study was conducted at Hayatabad Medical Complex (HMC), Peshawar, with the objective of characterizing the clinical features, comorbidities, antibiotic regimens, and management outcomes of patients diagnosed with DFI. Clinical records of 341 patients admitted over a three-month period were reviewed. A male predominance was observed, with the highest prevalence noted among individuals aged 40–60 years. The majority of cases involved insulin-dependent diabetes mellitus, and an extended disease duration was identified as a major predisposing factor for DFI development. The mean hospitalization period was 25 days. Notably, complications such as peripheral neuropathy, diabetic nephropathy, and peripheral vasculopathy were more frequently documented in patients aged 65 years and older. Empirical treatment commonly involved poly-antibiotic regimens, which were administered in 64.81% of cases, underscoring the polymicrobial nature and severity of infections encountered. An amputation rate of 44.07% was recorded, which exceeds figures reported in comparable regional studies and is likely attributable to delayed clinical presentation and advanced stages of infection at the time of admission. The findings underscore the urgent need for enhanced early screening protocols, timely initiation of pathogen-targeted antimicrobial therapy, and multidisciplinary surgical intervention to reduce the risk of lower extremity amputation and the associated socio-economic burden.</p></abstract>
      <kwd-group>
        <kwd>Diabetic foot infections</kwd>
        <kwd>Neuropathy</kwd>
        <kwd>Nephropathy</kwd>
        <kwd>Vasculopathy</kwd>
        <kwd>Antibiotics</kwd>
        <kwd>Amputation</kwd>
        <kwd>Poly-antibiotic therapy</kwd>
      </kwd-group>
      <counts>
        <count count-type="contributors" count="2"/>
        <fig-count count="4"/>
        <table-count count="4"/>
        <ref-count count="28"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>1. Introduction</title>
      <p>Diabetes mellitus is a serious global health concern, affecting approximately 422 million individuals worldwide and leading to more than 2 million deaths annually (<xref ref-type="bibr" rid="ref_7">Cousin et al., 2022</xref>). Diabetic foot infection (DFI) is a chronic condition of ulceration of poorly controlled and long-term diabetic patients (<xref ref-type="bibr" rid="ref_23">Raja et al., 2023</xref>). Among diabetic patients, 15% will develop foot ulcers. Foot infection is poorly treatable, and 14-24% will require amputation (<xref ref-type="bibr" rid="ref_5">CDC, 2020</xref>). The psychological burden associated with potential limb loss has been reported to exceed even the fear of death in many patients (<xref ref-type="bibr" rid="ref_6">Chastain et al., 2019</xref>).</p><p>Once infection develops in diabetic patients, it is difficult to cure it, depending on the severity of infection (<xref ref-type="bibr" rid="ref_14">Lavery et al., 2006</xref>). The mortality rate of DFI is more than that of prostate and breast cancer (<xref ref-type="bibr" rid="ref_2">Armstrong et al., 2007</xref>). Patients with severe infection have a substantial risk of mortality (<xref ref-type="bibr" rid="ref_28">Wukich et al., 2018</xref>).</p><p>Open wounds are the major cause of DFI in diabetic patients (<xref ref-type="bibr" rid="ref_11">Glenn et al., 2017</xref>; <xref ref-type="bibr" rid="ref_12">Hobizal &amp;amp; Wukich, 2012</xref>). According to some researchers, patients with wounds are more likely to get infections than those with intact skin (<xref ref-type="bibr" rid="ref_14">Lavery et al., 2006</xref>). Ulcerations are a common risk factor of DFI (<xref ref-type="bibr" rid="ref_27">Walsh et al., 2016</xref>), and other risk factors include neuropathy, nephropathy, vasculopathy, prior amputation, and walking barefoot (<xref ref-type="bibr" rid="ref_15">Lazzarini et al., 2018</xref>). Researchers have suggested that ulceration significantly increases mortality rate in this group (<xref ref-type="bibr" rid="ref_24">Robbins et al., 2008</xref>). DFI development and progression are multifactorial health concerns, breaching the skin and making it susceptible to microbes (<xref ref-type="bibr" rid="ref_14">Lavery et al., 2006</xref>). <italic>Staph. aureus, P. aeruginosa, E. coli</italic>,<italic> </italic>etc. are the common bacteria of DFI.</p><p>Anti-microbial resistance has further complicated the rising incidence of DFI. Common microbes, found in infected feet, have developed resistance to most of the antibiotics. New molecular techniques have solved the problem of uncultivable microbes but clinicians face challenges in treatment, i.e., which pathogen should be targeted (<xref ref-type="bibr" rid="ref_25">Singh et al., 2023</xref>).</p><p>The incumbent study aims to examine the demographic factors of patients suffering from DFI and record clinical history, management strategies, and antibiotic prescribing patterns.</p><p>DFI remains a serious problem with prolonged hospitalization, high morbidity and high mortality rates, often leading to severe complications. There is a limited understanding of how demography, clinical records, and antibiotic prescribing patterns play roles in the care and management of DFI, despite advancement. Inappropriate antibiotic prescription leads to prolonged hospitalization and poor clinical outcomes. The current study focuses on carefully examining the demographic factor, clinical history, management strategies, and antibiotic prescribing patterns to improve the patients’ care and management.</p>
    </sec>
    <sec sec-type="">
      <title>2. Methodology</title>
      <p>A prospective and observational type of study was conducted at Hayatabad Medical Complex (HMC) and Peshawar. First, ethical approval was taken from the Post Graduate Medical Institute (PGMI), Hayat Abad Peshawar. Then, through a proper channel, permission was taken from the Medical Director (MD) and Deputy Medical Superintendent (DMS) of HMC, the Head of the Endocrinology Ward, and the Head of the Microbiology Section.</p><p>The study was carried out over a period of three months, from April 15, 2017 to July 15, 2017, during which a total of 341 patients diagnosed with DFI were examined. In this study, the inclusion criteria were specifically focused on patients diagnosed with diabetes mellitus and DFI. The primary aim was to assess the prevalence and characteristics of foot infections in individuals with diabetes, as these are common complications that can lead to severe health issues if left untreated. The study intentionally excluded patients who had other types of infections, such as upper and lower respiratory tract infections, urinary tract infections, or any other non-foot-related infections. This exclusion was essential to ensure that the study results were concentrated on DFI alone, revealing distinct pathophysiological mechanisms, risk factors, and treatment approaches. By narrowing the scope to just DFI, the research aimed to provide more specific insights into how the infection develops and progresses in diabetic patients. This also allowed for a clearer understanding of the impact of diabetes on foot health, ensuring that the outcomes are directly applicable to managing and preventing diabetic foot complications.</p><p>During observation, patients’ demography, clinical history, antibiotic prescription and management outcomes were recorded in a history sheet, including name, age, sex, address, type of diabetes, durations of diabetes and diabetic foot, hospital stay, diabetic shoes, imputation (whether advised or not), medication (whether insulin dependent or not), number of antibiotics used and effectiveness. All these were present in the questionnaire entitled “Clinical Record of Diabetic Foot”. Examinations of every patient were done 2-3 times and the observation, effectiveness and improvement of the infection were noted.</p><p>After collecting complete information on patients suffering from DFI, a statistical analysis was applied. </p>
    </sec>
    <sec sec-type="results">
      <title>3. Results</title>
      <p>In this study, a total of 341 patients were examined at HMC, Peshawar, in a three-month period. In the current study, the incidence rate of DFI is 60.1% among the male patients and is 38.9% among the female ones. The p-value is about 0.003, which is statistically significant. In terms of age, the patients were divided into five groups, namely less than 30, 31-40, 41-50, 51-60, and above 60. The corresponding incidence rates are 5.27%, 16.12%, 36.65%, 27.27%, and 14.66%, respectively, and the p-value is less than 0.00001. However, patients using insulin account for 7.33%, and those not using insulin account for 92.66%, with the p-value being less than 0.00001. It demonstrates a significant result. The demographic details of the patients are given in <xref ref-type="table" rid="table_1">Table 1</xref>.</p>
      
        <table-wrap id="table_1">
          <label>Table 1</label>
          <caption>
            <title>Demography of DFI</title>
          </caption>
          <table><tbody><tr><td><p>Variable</p></td><td><p>Categories</p></td><td><p>Frequency (n)</p></td><td><p>Percentage (%)</p></td><td><p>p-value</p></td></tr><tr><td rowspan="2"><p>Sex</p></td><td><p>Male</p></td><td><p>220</p></td><td><p>61.10%</p></td><td rowspan="2"><p>≈ 0.003</p></td></tr><tr><td><p>Female</p></td><td><p>140</p></td><td><p>38.90%</p></td></tr><tr><td rowspan="5"><p>Age</p></td><td><p>&amp;amp;lt; 30</p></td><td><p>18</p></td><td><p>5.27%</p></td><td rowspan="5"><p>&amp;amp;lt; 0.00001</p></td></tr><tr><td><p>31 – 40</p></td><td><p>55</p></td><td><p>16.12%</p></td></tr><tr><td><p>41 – 50</p></td><td><p>125</p></td><td><p>36.65%</p></td></tr><tr><td><p>51 – 60</p></td><td><p>93</p></td><td><p>27.27%</p></td></tr><tr><td><p>&amp;amp;gt; 60</p></td><td><p>50</p></td><td><p>14.66%</p></td></tr><tr><td rowspan="2"><p>Diabetes type</p></td><td><p>Insulin dependent</p></td><td><p>25</p></td><td><p>7.33%</p></td><td rowspan="2"><p>&amp;amp;lt; 0.00001</p></td></tr><tr><td><p>Insulin independent</p></td><td><p>316</p></td><td><p>92.66%</p></td></tr></tbody></table>
        </table-wrap>
      
      <p><xref ref-type="fig" rid="fig_1">Figure 1</xref> demonstrates the duration of diabetes mellitus since onset and provides a visual representation. It shows how long each patient has been living with the condition. <xref ref-type="fig" rid="fig_2">Figure 2</xref> shows the current status of glycaemia. The bar chart represents the details of fasting blood sugar (FBS) and random blood sugar (RBS) levels of the diabetic patients with foot infections.</p>
      
        <fig id="fig_1">
          <label>Figure 1</label>
          <caption>
            <title>History of diabetes mellitus</title>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://media.acadlore.com/assets/media/2025/4/img_6r3XGkcQT-NoyoAx.png"/>
        </fig>
      
      
        <fig id="fig_2">
          <label>Figure 2</label>
          <caption>
            <title>Current status of glycaemia</title>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://media.acadlore.com/assets/media/2025/4/img_3YpvWygV_GNZRngP.png"/>
        </fig>
      
      <p>Upon careful examination of the patients, DFI duration was categorized since its onset, i.e., infected less than 1 month (46.33%), 1-2 months (25.21%), and more than 2 months (28.44%). The p-value is 0.002, which is statistically significant (p &amp;amp;lt; 0.05). This suggests that the distribution across the infection duration categories is not uniform and potentially meaningful. In terms of prolonged hospitalization, 2.93% of patients stayed in the hospital for less than 1 month, 23.46% for 11-20 days, 47.8% for 21-30 days, and 25.80% for more than 30 days. The p-value is 4.23 × 10⁻¹⁸, which is highly significant, indicating a very strong difference in the distribution of hospital stay durations, as shown in <xref ref-type="table" rid="table_2">Table 2</xref>.</p>
      
        <table-wrap id="table_2">
          <label>Table 2</label>
          <caption>
            <title>History of DFI and hospital stay</title>
          </caption>
          <table><tbody><tr><td colspan="3"><p>History of DFI</p></td><td><p>p-value </p></td></tr><tr><td><p>Less than 1 month</p></td><td><p>158</p></td><td><p>46.33%</p></td><td rowspan="3"><p>0.002</p></td></tr><tr><td><p>1 – 2 months</p></td><td><p>86</p></td><td><p>25.21%</p></td></tr><tr><td><p>More than 2 months</p></td><td><p>97</p></td><td><p>28.44%</p></td></tr><tr><td colspan="3"><p>Hospital Stay</p></td><td><p>p-value</p></td></tr><tr><td><p>Less than 10 days</p></td><td><p>10</p></td><td><p>02.93%</p></td><td rowspan="4"><p>4.23 × 10⁻¹⁸</p></td></tr><tr><td><p>11 – 20 days</p></td><td><p>80</p></td><td><p>23.46%</p></td></tr><tr><td><p>21 – 30 days</p></td><td><p>163</p></td><td><p>47.80%</p></td></tr><tr><td><p>More than 30 days</p></td><td><p>88</p></td><td><p>25.80%</p></td></tr></tbody></table>
        </table-wrap>
      
      <p>Common DFI complications include neuropathy, nephropathy and vasculopathy, and their occurrences are shown in <xref ref-type="fig" rid="fig_3">Figure 3</xref>. </p>
      
        <fig id="fig_3">
          <label>Figure 3</label>
          <caption>
            <title>Complications of DFI</title>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://media.acadlore.com/assets/media/2025/4/img_-QFaxk-HLgZHmCTo.png"/>
        </fig>
      
      <p>DFI management includes insulin prescription, antibiotic therapy, surgical intervention and specific shoe usage for diabetic patients. The treatment and management of DFI depend upon its severity and duration. As shown in <xref ref-type="table" rid="table_3">Table 3</xref>, the diabetic patients using insulin account for 89.14% and those not using insulin account for 10.85%. Different numbers of antibiotics were prescribed, such as 1 (35.19%), 2 (31.67%), 3 (19.06%), 4 (8.21%), and 5 (5.86%). Surgical intervention includes imputation. 44.07% of patients were advised for imputation while 63.93% were not. The diabetic shoes were advised for all diabetic patients.</p>
      
        <table-wrap id="table_3">
          <label>Table 3</label>
          <caption>
            <title>Management of the diabetic foot ulcer</title>
          </caption>
          <table><tbody><tr><td colspan="3"><p>Insulin Prescription</p></td></tr><tr><td><p>Prescribed insulin</p></td><td><p>304</p></td><td><p>89.14%</p></td></tr><tr><td><p>Not prescribed insulin</p></td><td><p>37</p></td><td><p>10.85%</p></td></tr><tr><td colspan="3"><p>Number of Antibiotics Prescribed</p></td></tr><tr><td><p>1</p></td><td><p>120</p></td><td><p>35.19%</p></td></tr><tr><td><p>2</p></td><td><p>108</p></td><td><p>31.67%</p></td></tr><tr><td><p>3</p></td><td><p>65</p></td><td><p>19.06%</p></td></tr><tr><td><p>4</p></td><td><p>28</p></td><td><p>08.21%</p></td></tr><tr><td><p>5</p></td><td><p>20</p></td><td><p>05.86%</p></td></tr><tr><td colspan="3"><p>Amputation</p></td></tr><tr><td><p>Advised amputation</p></td><td><p>151</p></td><td><p>44.07%</p></td></tr><tr><td><p>Not advised amputation</p></td><td><p>190</p></td><td><p>63.93%</p></td></tr><tr><td colspan="3"><p>Shoes Advised</p></td></tr><tr><td><p>Shoes advised</p></td><td><p>341</p></td><td><p>100%</p></td></tr><tr><td><p>Shoes not advised</p></td><td><p>--</p></td><td><p>--</p></td></tr></tbody></table>
        </table-wrap>
      
      
        <sec>
          
            <title>3.1. Antibiotic prescription and efficacy</title>
          
          <p>In the current study, it can be noted that antibiotics were prescribed to individuals infected with diabetic foot. The most commonly prescribed antibiotic was Augmentin. It was given to most of the individuals (48 patients), with its effectiveness and non-effectiveness being recorded at 70.83% and 29.16%. Other antibiotics are Penro, Grasil, Tanzo, Moxiget, Cebac, Meropenem, Rocephin, Meroncan, Fuzidin, Cefzone, Calamox, Zyvox, Cleocin HCl, Colistin, Cipro, Abomox, Garamycin, Levaquin and Cefsol. Their effectiveness was recorded at 38.29%, 87.50%, 86.67%, 50%, 58.33%, 66.66%, 33.33%, 66.66%, 60%, 33.33%, 80%, 86.66%, 26.66%, 100%, 56.66%, 25%, 66.66%, 100%, and 75%, respectively. And their non-effectiveness was recorded at 61.7%, 14.28%, 13.33%, 50%, 41.66%, 33.33%, 66.66%, 33.33%, 40%, 66.66%, 20%, 13.33%, 73.33%, 0%, 44.33%, 75%, 33.33%, 0% and 25%, respectively. Flagyl is a protozoal antibiotic given to most of the patients. Its effectiveness was not mentioned in <xref ref-type="fig" rid="fig_4">Figure 4</xref>. The test yielded a p-value of approximately 8.3 × 10⁻³⁵, which is highly significant (p &amp;amp;lt; 0.05), indicating that the effectiveness of treatment varies significantly among the antibiotics.</p>
          
            <fig id="fig_4">
              <label>Figure 4</label>
              <caption>
                <title>Antibiotic prescription and efficacy</title>
              </caption>
              <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://media.acadlore.com/assets/media/2025/4/img_j7EPoY1kE8C1ookN.png"/>
            </fig>
          
        </sec>
      
      
        <sec>
          
            <title>3.2. Routes of antibiotic administration</title>
          
          <p>Mostly antibiotics are given orally. But in the case of DFI, antibiotics were given either intravenously (IV) or intramuscularly (IM). Flagyl was mostly administered as IV and in few cases was orally. IV-administered antibiotics include Penro, Grasil, Tanzo, Augmentin, Cebac, Meronem, Rocephin, Merocan, Cefzone, Calamox, Zyvox, Cleocin, Colistin, Cipro, Garamycin, and Levaquin. Only Penro was administered as IM. It can be noted that Levaquin, Cleocin HCl and Calamox were also administered orally. Antibiotics administered only orally include Moxiget and Avelox. It can be noted that Fuzidin was the only topical antibiotic (<xref ref-type="table" rid="table_4">Table 4</xref>). </p>
          
            <table-wrap id="table_4">
              <label>Table 4</label>
              <caption>
                <title>Routes of antibiotic administration</title>
              </caption>
              <table><tbody><tr><td rowspan="2"><p>S. No</p></td><td rowspan="2"><p>Trade Name</p></td><td colspan="4"><p>Route of Administration</p></td></tr><tr><td><p>IV</p></td><td><p>IM</p></td><td><p>Oral</p></td><td><p>Topical</p></td></tr><tr><td><p>1</p></td><td><p>Flagyl</p></td><td><p>*</p></td><td><p>-</p></td><td><p>*</p></td><td><p>-</p></td></tr><tr><td><p>2</p></td><td><p>Penro</p></td><td><p>*</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>3</p></td><td><p>Grasil</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>4</p></td><td><p>Tanzo</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>5</p></td><td><p>Augmentin</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>6</p></td><td><p>Moxiget</p></td><td><p>-</p></td><td><p>-</p></td><td><p>*</p></td><td><p>-</p></td></tr><tr><td><p>7</p></td><td><p>Cebac</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>8</p></td><td><p>Meronem</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>9</p></td><td><p>Rocephin</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>10</p></td><td><p>Merocan</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>11</p></td><td><p>Fuzidin</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td><td><p>*</p></td></tr><tr><td><p>12</p></td><td><p>Cefzone</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>13</p></td><td><p>Calamox</p></td><td><p>*</p></td><td><p>-</p></td><td><p>*</p></td><td><p>-</p></td></tr><tr><td><p>14</p></td><td><p>Zyvox</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>15</p></td><td><p>Cleocin HCl</p></td><td><p>*</p></td><td><p>-</p></td><td><p>*</p></td><td><p>-</p></td></tr><tr><td><p>16</p></td><td><p>Colistin</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>17</p></td><td><p>Cipro</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>18</p></td><td><p>Avelox</p></td><td><p>-</p></td><td><p>-</p></td><td><p>*</p></td><td><p>-</p></td></tr><tr><td><p>19</p></td><td><p>Garamycin</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>20</p></td><td><p>Levaquin</p></td><td><p>*</p></td><td><p>-</p></td><td><p>*</p></td><td><p>-</p></td></tr><tr><td><p>21</p></td><td><p>Cefsol</p></td><td><p>*</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table>
            </table-wrap>
          
        </sec>
      
    </sec>
    <sec sec-type="discussion">
      <title>4. Discussion</title>
      <p>DFI is a serious issue worldwide, as its prevalence continuously rises, leading to serious socio-economic challenges. The current study was conducted in various hospitals across KP. 341 patients were examined over a three-month period, and their clinical records and medications (antibiotic prescriptions) were documented.</p><p>According to <xref ref-type="bibr" rid="ref_9">Gadepalli et al. (2006)</xref>,<italic> </italic>male patients (85%) were predominant, whereas female ones accounted for 15%. However, in the current study, the proportion is slightly lower. The predominance of male patients in both studies may be attributed to the fact that the male is engaged in fieldwork and is more exposed to the infection than the female. Some researchers have suggested that slower healing in diabetic patients increases susceptibility to the infection (<xref ref-type="bibr" rid="ref_26">Vowden, 1997</xref>).</p><p>It can be noted that people of 40-60 years old have the highest risk, aligning with the findings of <xref ref-type="bibr" rid="ref_9">Gadepalli et al. (2006)</xref>,<italic> </italic>who recorded 57 ± 11.29 years. Similarly, the insulin-dependent diabetic patients’ proportion aligns with the study by <xref ref-type="bibr" rid="ref_3">Assaad-Khalil et al. (2014)</xref>, who reported 96.75%.</p><p>The duration of diabetes since its onset is also a significant factor in the occurrence and development of DFI. The incumbent study shows a similar result to previous studies (54.5%) (<xref ref-type="bibr" rid="ref_9">Gadepalli et al., 2006</xref>). DFI often leads to prolonged hospitalization, depending on its severity. The clinical history shows 25 days of hospitalization on average, comparable to the study of <xref ref-type="bibr" rid="ref_9">Gadepalli et al. (2006)</xref>, who reported 20 ± 20 days.</p><p>Prolonged DFI leads to complications like neuropathy, nephropathy, vasculopathy, cardiopathy, etc. The percentage (41.6%) of the previous result is higher than that of the current study. However, this study shows a higher incidence in patients aged more than 65 years old (<xref ref-type="bibr" rid="ref_1">Akkus &amp;amp; Sert, 2022</xref>). Whereas nephropathy shows contrasting results with previous studies. The variation is maybe caused by the fact that the current study focuses on DFI while the previous research focuses on all diabetic patients (<xref ref-type="bibr" rid="ref_8">Dòria et al., 2016</xref>). The vasculopathy result aligns with the study by <xref ref-type="bibr" rid="ref_13">Ikem et al. (2010)</xref>, and has few discrepancies with some previous reports (<xref ref-type="bibr" rid="ref_22">Rahman et al., 2009</xref>).</p><p>Poly-antibiotic therapy depends on the severity of infection. In this study, the participants were divided into five groups based on the numbers of prescribed anti-microbial drugs. However, in previous studies, the category includes a poly-antibiotic therapy with more than two antibiotics. The antibiotic prescription patterns in DFI in the incumbent study reveal a slight difference. The current study demonstrates that 64.81% of patients used more than two prescribed antibiotics compared to the previous results (57.3%). The slight difference depends on the severity of infection (<xref ref-type="bibr" rid="ref_19">Nagaya et al., 2024</xref>).</p><p>The progression of DFI and related complications leads to amputations. The amputation incidence rate in the current study is 44.07% compared to earlier research (31%). The discrepancies may be caused by delayed presentations, poor response to the prescribed antibiotics, advanced infection stage or the effectiveness of early surgical intervention strategies (<xref ref-type="bibr" rid="ref_16">Luo et al., 2024</xref>).</p><p>In this study, the most commonly prescribed anti-microbial drug was Augmentin. Its efficacy was 70.83%, aligning with its established role as the first-line treatment for mild and moderate infection (<xref ref-type="bibr" rid="ref_10">Gariani et al., 2019</xref>). On the other hand, the non-effectiveness shows antibiotic resistance, a significant concern in chemotherapy of DFI (<xref ref-type="bibr" rid="ref_21">Peter-Riesch, 2016</xref>). The variation in antibiotic prescription demonstrates the poly-microbial nature of infection, requiring broad-spectrum antibiotics to completely cover gram-positive and gram-negative strains. Prescribed antibiotics included Penro, Grasil, Moxiget, and Meropenem.</p><p>The variation in efficacy of prescribed anti-microbial drugs like Penro (38.29%) and Cefzone (33.33%) emphasizes the importance of local surveillance of antibiotic resistance and is considered a growing concern in diabetic patients, specifically with the extensive use of broad-spectrum antibiotics like Cefepime and Meropenem. The 100% efficacy rate of Zyvox and Levaquin suggests that these may be the promising and drugs of choice for the treatment of poly-microbial and multi-drug-resistant infections (<xref ref-type="bibr" rid="ref_4">Bouza, 2009</xref>).</p><p>For treating DFI, the most common routes of antibiotic administration were IV and IM as these require vigorous and intensive management. This aligns with previous reports that Penro, Grasil, and Meropenem antibiotic are administered IV, particularly in severe and complicated infections. For mild and moderate infections, Moxiget and Avelox were administered orally and Fuzidin was used for localized wound care as a topical antibiotic (<xref ref-type="bibr" rid="ref_18">Mougakou et al., 2023</xref>; <xref ref-type="bibr" rid="ref_20">Olid et al., 2015</xref>).</p><p>The current study highlights the importance of a critical need for proper antibiotic therapy in treating DFI, as misuse of antibiotics can lead to high antibiotic resistance that could worsen the issue. Previous reports emphasize the antibiotic stewardship program to guide clinical practitioners in choosing effective therapeutic treatment to minimize resistance concerns (<xref ref-type="bibr" rid="ref_17">MacDougall &amp;amp; Polk, 2005</xref>). The inefficacy of anti-microbial drugs like Cefzone and Penro further stresses the need for continuous surveillance of local resistance patterns. Furthermore, the frequent use of IV antibiotic administration underscores the importance of infection control measures to prevent nosocomial infection and multi-drug-resistant strain spreading. It is emphasized that the region-specific treatment guideline should be developed based on local resistance data to optimize and control resistance development.</p>
    </sec>
    <sec sec-type="">
      <title>5. Conclusion</title>
      <p>This study highlights the growing severity and socio-economic burden of DFI, which continues to present significant challenges to healthcare systems worldwide. The findings, which align with and diverge from previous research, emphasize the importance of age, gender, and insulin dependency as significant risk factors for DFI. The study underscores the need for effective management strategies, particularly given the complications and prolonged hospitalization associated with advanced stages of DFI. Compared to previous reports, the higher incidence of amputations observed in this study (44.07%) reflects the critical need for early intervention and better antibiotic stewardship.</p><p>The findings also point to a concerning trend of antibiotic resistance, particularly with commonly prescribed drugs like Penro and Cefzone, which highlights the need for vigilant surveillance of local resistance patterns. The predominance of IV and IM antibiotic administration in severe cases further emphasizes the intensive nature of treatment required for DFI. These results underscore the urgent need for region-specific treatment guidelines to combat multi-drug-resistant infections and optimize patient care.</p><p>Looking to the future, it is crucial to implement more robust antibiotic stewardship programs aimed at reducing the misuse of antibiotics and preventing the development of resistance. Regular monitoring of antibiotic efficacy and resistance patterns is essential for adapting treatment strategies to local needs. Additionally, improving early diagnosis and timely intervention could prevent the progression of DFI, reducing the incidence of amputations and associated complications. Lastly, ongoing research should focus on the development of more effective, localized therapies that address the poly-microbial nature of DFI, ensuring better patient outcomes and reduced healthcare costs.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      
    </ack>
    <app-group>
      <app>
        <title>Appendix</title>
        
      </app>
    </app-group>
    <notes>
      <title>Author Contributions</title>
      
    </notes>
    <notes>
      <title>Funding</title>
      
    </notes>
    <notes>
      <title>Informed Consent Statement</title>
      
    </notes>
    <notes>
      <title>Data Availability Statement</title>
      <p>The data used to support the research findings are available from the corresponding author upon request.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="ref_1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <volume>13</volume>
          <page-range>1106-1121</page-range>
          <issue>12</issue>
          <year>2022</year>
          <person-group person-group-type="author">
            <name>
              <surname>Akkus</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sert</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.4239/wjd.v13.i12.1106.</pub-id>
          <article-title>Diabetic foot ulcers: A devastating complication of diabetes mellitus continues non-stop in spite of new medical treatment modalities</article-title>
          <source>World J. Diabetes</source>
        </element-citation>
      </ref>
      <ref id="ref_2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <volume>4</volume>
          <page-range>286-287</page-range>
          <issue>4</issue>
          <year>2007</year>
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>D. G.</given-names>
            </name>
            <name>
              <surname>Wrobel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>J. M.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1111/j.1742-481X.2007.00392.x.</pub-id>
          <article-title>Guest editorial: Are diabetes‐related wounds and amputations worse than cancer?</article-title>
          <source>Int. Wound J.</source>
        </element-citation>
      </ref>
      <ref id="ref_3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <volume>9</volume>
          <page-range>297-303</page-range>
          <issue>4</issue>
          <year>2014</year>
          <person-group person-group-type="author">
            <name>
              <surname>Assaad-Khalil</surname>
              <given-names>S. H.</given-names>
            </name>
            <name>
              <surname>Zaki</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rehim</surname>
              <given-names>A. A.</given-names>
            </name>
            <name>
              <surname>Megallaa</surname>
              <given-names>M. H.</given-names>
            </name>
            <name>
              <surname>Gaber</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Gamal</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Rohoma</surname>
              <given-names>K. H.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1016/j.pcd.2014.10.010.</pub-id>
          <article-title>Prevalence of diabetic foot disorders and related risk factors among Egyptian subjects with diabetes</article-title>
          <source>Prim. Care Diabetes</source>
        </element-citation>
      </ref>
      <ref id="ref_4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <volume>15</volume>
          <page-range>44-52</page-range>
          <issue>Suppl. 7</issue>
          <year>2009</year>
          <person-group person-group-type="author">
            <name>
              <surname>Bouza</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1111/j.1469-0691.2009.03091.x.</pub-id>
          <article-title>New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus</article-title>
          <source>Clin. Microbiol. Infect.</source>
        </element-citation>
      </ref>
      <ref id="ref_5">
        <label>5.</label>
        <element-citation publication-type="report">
          <article-title>National diabetes statistics report, 2020: Estimates of diabetes and its burden in the United States</article-title>
          <source>, https://stacks.cdc.gov/view/cdc/85309</source>
          <year>2020</year>
          <publisher-name>U.S. Department of Health and Human Services</publisher-name>
        </element-citation>
      </ref>
      <ref id="ref_6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <volume>36</volume>
          <page-range>381-395</page-range>
          <issue>3</issue>
          <year>2019</year>
          <person-group person-group-type="author">
            <name>
              <surname>Chastain</surname>
              <given-names>C. A.</given-names>
            </name>
            <name>
              <surname>Klopfenstein</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Serezani</surname>
              <given-names>C. H.</given-names>
            </name>
            <name>
              <surname>Aronoff</surname>
              <given-names>D. M.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1016/j.cpm.2019.02.004.</pub-id>
          <article-title>A clinical review of diabetic foot infections</article-title>
          <source>Clin. Podiatr. Med. Surg.</source>
        </element-citation>
      </ref>
      <ref id="ref_7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <volume>10</volume>
          <page-range>655-667</page-range>
          <issue>9</issue>
          <year>2022</year>
          <person-group person-group-type="author">
            <name>
              <surname>Cousin</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>M. I.</given-names>
            </name>
            <name>
              <surname>Ong</surname>
              <given-names>K. L.</given-names>
            </name>
            <name>
              <surname>Lozano</surname>
              <given-names>R. et al.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1016/S2213-8587(22)00186-3.</pub-id>
          <article-title>Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019</article-title>
          <source>Lancet Diabetes Endocrinol.</source>
        </element-citation>
      </ref>
      <ref id="ref_8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <volume>2016</volume>
          <page-range>7217586</page-range>
          <issue>1</issue>
          <year>2016</year>
          <person-group person-group-type="author">
            <name>
              <surname>Dòria</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rosado</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Pacheco</surname>
              <given-names>L. R.</given-names>
            </name>
            <name>
              <surname>Hernández</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Betriu</surname>
              <given-names>À.</given-names>
            </name>
            <name>
              <surname>Valls</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Franch-Nadal</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Fernández</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mauricio</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1155/2016/7217586.</pub-id>
          <article-title>Prevalence of diabetic foot disease in patients with diabetes mellitus under renal replacement therapy in Lleida, Spain</article-title>
          <source>Biomed Res. Int.</source>
        </element-citation>
      </ref>
      <ref id="ref_9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <volume>29</volume>
          <page-range>1727-1732</page-range>
          <issue>8</issue>
          <year>2006</year>
          <person-group person-group-type="author">
            <name>
              <surname>Gadepalli</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Dhawan</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Sreenivas</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Kapil</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ammini</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Chaudhry</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.2337/dc06-0116.</pub-id>
          <article-title>A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital</article-title>
          <source>Diabetes Care</source>
        </element-citation>
      </ref>
      <ref id="ref_10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <volume>21</volume>
          <page-range>1483-1486</page-range>
          <issue>6</issue>
          <year>2019</year>
          <person-group person-group-type="author">
            <name>
              <surname>Gariani</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Lebowitz</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kressmann</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>von Dach</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Sendi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Waibel</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Berli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lipsky</surname>
              <given-names>B. A.</given-names>
            </name>
            <name>
              <surname>Uçkay</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1111/dom.13651.</pub-id>
          <article-title>Oral amoxicillin‐clavulanate for treating diabetic foot infections</article-title>
          <source>Diabetes, Obes. Metab.</source>
        </element-citation>
      </ref>
      <ref id="ref_11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <volume>11</volume>
          <page-range>FC01-FC05</page-range>
          <issue>8</issue>
          <year>2017</year>
          <person-group person-group-type="author">
            <name>
              <surname>Glenn</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Borecki</surname>
              <given-names>A. A.</given-names>
            </name>
            <name>
              <surname>Bradshaw</surname>
              <given-names>C. et al.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.7860/JCDR/2017/25539.10395.</pub-id>
          <article-title>Patient demographic and clinician factors in antibiotic prescribing for upper respiratory tract infections in the Australian Capital Territory from 2006-2015</article-title>
          <source>J. Clin. Diagnostic Res.</source>
        </element-citation>
      </ref>
      <ref id="ref_12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <volume>3</volume>
          <page-range>18409</page-range>
          <issue>1</issue>
          <year>2012</year>
          <person-group person-group-type="author">
            <name>
              <surname>Hobizal</surname>
              <given-names>K. B.</given-names>
            </name>
            <name>
              <surname>Wukich</surname>
              <given-names>D. K.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.3402/dfa.v3i0.18409.</pub-id>
          <article-title>Diabetic foot infections: Current concept review</article-title>
          <source>Diabet. Foot Ankle</source>
        </element-citation>
      </ref>
      <ref id="ref_13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <volume>20</volume>
          <page-range>114-117</page-range>
          <issue>4</issue>
          <year>2010</year>
          <person-group person-group-type="author">
            <name>
              <surname>Ikem</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ikem</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Adebayo</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Soyoye</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1016/j.foot.2010.09.002.</pub-id>
          <article-title>An assessment of peripheral vascular disease in patients with diabetic foot ulcer</article-title>
          <source>Foot</source>
        </element-citation>
      </ref>
      <ref id="ref_14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <volume>29</volume>
          <page-range>1288-1293</page-range>
          <issue>6</issue>
          <year>2006</year>
          <person-group person-group-type="author">
            <name>
              <surname>Lavery</surname>
              <given-names>L. A.</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>D. G.</given-names>
            </name>
            <name>
              <surname>Wunderlich</surname>
              <given-names>R. P.</given-names>
            </name>
            <name>
              <surname>Mohler</surname>
              <given-names>M. J.</given-names>
            </name>
            <name>
              <surname>Wendel</surname>
              <given-names>C. S.</given-names>
            </name>
            <name>
              <surname>Lipsky</surname>
              <given-names>B. A.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.2337/dc05-2425.</pub-id>
          <article-title>Risk factors for foot infections in individuals with diabetes</article-title>
          <source>Diabetes Care</source>
        </element-citation>
      </ref>
      <ref id="ref_15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <volume>35</volume>
          <page-range>1297-1299</page-range>
          <issue>9</issue>
          <year>2018</year>
          <person-group person-group-type="author">
            <name>
              <surname>Lazzarini</surname>
              <given-names>P. A.</given-names>
            </name>
            <name>
              <surname>Pacella</surname>
              <given-names>R. E.</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>D. G.</given-names>
            </name>
            <name>
              <surname>Van Netten</surname>
              <given-names>J. J.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1111/dme.13680.</pub-id>
          <article-title>Diabetes-related lower-extremity complications are a leading cause of the global burden of disability</article-title>
          <source>Diabet. Med.</source>
        </element-citation>
      </ref>
      <ref id="ref_16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <volume>21</volume>
          <page-range>e14931</page-range>
          <issue>7</issue>
          <year>2024</year>
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>Z.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1111/iwj.14931.</pub-id>
          <article-title>The incidence of lower extremity amputation and its associated risk factors in patients with diabetic foot ulcers: A meta‐analysis</article-title>
          <source>Int. Wound J.</source>
        </element-citation>
      </ref>
      <ref id="ref_17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <volume>18</volume>
          <page-range>638-656</page-range>
          <issue>4</issue>
          <year>2005</year>
          <person-group person-group-type="author">
            <name>
              <surname>MacDougall</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Polk</surname>
              <given-names>R. E.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1128/cmr.18.4.638-656.2005.</pub-id>
          <article-title>Antimicrobial stewardship programs in health care systems</article-title>
          <source>Clin. Microbiol. Rev.</source>
        </element-citation>
      </ref>
      <ref id="ref_18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <volume>14</volume>
          <page-range>251-263</page-range>
          <issue>2</issue>
          <year>2023</year>
          <person-group person-group-type="author">
            <name>
              <surname>Mougakou</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mastrogianni</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Kyziroglou</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tziomalos</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1007/s13300-022-01357-2.</pub-id>
          <article-title>The role of novel antibiotics in the management of diabetic foot infection</article-title>
          <source>Diabetes Ther.</source>
        </element-citation>
      </ref>
      <ref id="ref_19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <volume>16</volume>
          <page-range>e60139</page-range>
          <issue>5</issue>
          <year>2024</year>
          <person-group person-group-type="author">
            <name>
              <surname>Nagaya</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Deva</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Jagadeesh</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Emmanuel</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Narayan</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.7759/cureus.60139.</pub-id>
          <article-title>Optimizing Antibiotic treatment for diabetic foot infections: A study from a tertiary public healthcare center in Puducherry, South India</article-title>
          <source>Cureus</source>
        </element-citation>
      </ref>
      <ref id="ref_20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <volume>9</volume>
          <page-range>CD009061</page-range>
          <year>2015</year>
          <person-group person-group-type="author">
            <name>
              <surname>Olid</surname>
              <given-names>A. S.</given-names>
            </name>
            <name>
              <surname>Solà</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Barajas‐Nava</surname>
              <given-names>L. A.</given-names>
            </name>
            <name>
              <surname>Gianneo</surname>
              <given-names>O. D.</given-names>
            </name>
            <name>
              <surname>Cosp</surname>
              <given-names>X. B.</given-names>
            </name>
            <name>
              <surname>Lipsky</surname>
              <given-names>B. A.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1002/14651858.CD009061.pub2.</pub-id>
          <article-title>Systemic antibiotics for treating diabetic foot infections</article-title>
          <source>Cochrane Database Syst. Rev.</source>
        </element-citation>
      </ref>
      <ref id="ref_21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <volume>31</volume>
          <page-range>108-134</page-range>
          <issue>2</issue>
          <year>2016</year>
          <person-group person-group-type="author">
            <name>
              <surname>Peter-Riesch</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1159/000439409.</pub-id>
          <article-title>The diabetic foot: The never-ending challenge</article-title>
          <source>Endocr. Dev.</source>
        </element-citation>
      </ref>
      <ref id="ref_22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <volume>25</volume>
          <page-range>428-433</page-range>
          <issue>3</issue>
          <year>2009</year>
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Moizuddin</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ahmad</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Salim</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Vasculopathy in patients with diabetic foot using doppler ultrasound</article-title>
          <source>Pakistan J. Med. Sci.</source>
        </element-citation>
      </ref>
      <ref id="ref_23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <volume>11</volume>
          <page-range>1684-1693</page-range>
          <issue>8</issue>
          <year>2023</year>
          <person-group person-group-type="author">
            <name>
              <surname>Raja</surname>
              <given-names>J. M.</given-names>
            </name>
            <name>
              <surname>Maturana</surname>
              <given-names>M. A.</given-names>
            </name>
            <name>
              <surname>Kayali</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Khouzam</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Efeovbokhan</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.12998/wjcc.v11.i8.1684.</pub-id>
          <article-title>Diabetic foot ulcer: A comprehensive review of pathophysiology and management modalities</article-title>
          <source>World J. Clin. Cases</source>
        </element-citation>
      </ref>
      <ref id="ref_24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <volume>98</volume>
          <page-range>489-493</page-range>
          <issue>6</issue>
          <year>2008</year>
          <person-group person-group-type="author">
            <name>
              <surname>Robbins</surname>
              <given-names>J. M.</given-names>
            </name>
            <name>
              <surname>Strauss</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Aron</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kuba</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kaplan</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.7547/0980489.</pub-id>
          <article-title>Mortality rates and diabetic foot ulcers: Is it time to communicate mortality risk to patients with diabetic foot ulceration?</article-title>
          <source>J. Am. Podiatr. Med. Assoc.</source>
        </element-citation>
      </ref>
      <ref id="ref_25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <volume>11</volume>
          <page-range>487-502</page-range>
          <issue>1</issue>
          <year>2023</year>
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Maity</surname>
              <given-names>M. K.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Babbar</surname>
              <given-names>N. S.</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Malik</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tandon</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Agrawal</surname>
              <given-names>B. K.</given-names>
            </name>
          </person-group>
          <article-title>Impact of antimicrobial resistance in diabetic foot infections</article-title>
          <source>J. Am. Podiatr. Med. Assoc.</source>
        </element-citation>
      </ref>
      <ref id="ref_26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <volume>6</volume>
          <page-range>4-8</page-range>
          <issue>1</issue>
          <year>1997</year>
          <person-group person-group-type="author">
            <name>
              <surname>Vowden</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.12968/jowc.1997.6.1.4.</pub-id>
          <article-title>Diabetic foot complications</article-title>
          <source>J. Wound Care</source>
        </element-citation>
      </ref>
      <ref id="ref_27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <volume>33</volume>
          <page-range>1493-1498</page-range>
          <issue>11</issue>
          <year>2016</year>
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>J. W.</given-names>
            </name>
            <name>
              <surname>Hoffstad</surname>
              <given-names>O. J.</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>M. O.</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>D. J.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1111/dme.13054.</pub-id>
          <article-title>Association of diabetic foot ulcer and death in a population‐based cohort from the United Kingdom</article-title>
          <source>Diabet. Med.</source>
        </element-citation>
      </ref>
      <ref id="ref_28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <volume>11</volume>
          <page-range>17-21</page-range>
          <issue>1</issue>
          <year>2018</year>
          <person-group person-group-type="author">
            <name>
              <surname>Wukich</surname>
              <given-names>D. K.</given-names>
            </name>
            <name>
              <surname>Raspovic</surname>
              <given-names>K. M.</given-names>
            </name>
            <name>
              <surname>Suder</surname>
              <given-names>N. C.</given-names>
            </name>
          </person-group>
          <pub-id pub-id-type="doi">10.1177/1938640017694722.</pub-id>
          <article-title>Patients with diabetic foot disease fear major lower-extremity amputation more than death</article-title>
          <source>Foot Ankle Spec.</source>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>